论文部分内容阅读
目的评价参附注射液在老年慢性心力衰竭患者中的治疗效果及其安全性。方法将61例老年慢性心力衰竭患者随机分为试验组和对照组,其中试验组30例,对照组31例。对照组给以卧床休息、间断吸氧及常规药物等支持治疗,试验组在常规治疗的基础上给予参附注射液100 m L稀释后静脉滴注,1次/天,疗程为2周。观察治疗前后各组患者心功能分级改善、BNP及左室射血分数等变化情况。结果 2组组内治疗前后的心功能分级改善、BNP及左室射血分数比较有显著性差异;2组之间比较试验组改善效果好于对照组,且无严重不良反应发生。结论参附注射液在老年慢性心力衰竭患者中的治疗效果明显,安全可靠,值得推广应用。
Objective To evaluate the therapeutic effect and safety of Shenfu Injection in senile patients with chronic heart failure. Methods Sixty-one elderly patients with chronic heart failure were randomly divided into experimental group and control group, with 30 cases in trial group and 31 cases in control group. The control group was given bed rest, intermittent oxygen and routine drugs and other supportive treatment. The experimental group was given Shenfu injection diluted 100 ml on the basis of routine treatment, once a day for 2 weeks. Before and after treatment, the improvement of cardiac function, BNP and left ventricular ejection fraction were observed. Results Before and after treatment, the scores of cardiac function improved, BNP and left ventricular ejection fraction were significantly different between two groups. The improvement effect of the two groups was better than that of the control group, and no serious adverse reactions occurred. Conclusion Shenfu injection in elderly patients with chronic heart failure treatment effect is obvious, safe and reliable, it is worth promoting the application.